The Design of Clinical Trials and Clinical Toxicology of the Nitroimidazole Misonidazole in Phase I Testing in the Radiation Therapy Oncology Group
The Radiation Therapy Oncology Group (RTOG) is the only organized cooperative group within the United States dedicated to the investigation of therapeutic radiology in the treatment of malignant disease. More than 25 institutions have joined together with support from the National Cancer Institute for a series of cooperative clinical trials in a number of disease sites and a wide range of new modalities. The goal of the RTOG is to improve the results of radiotherapy in the cure of cancer and in the palliation of metastatic disease.
KeywordsRadiation Therapy Oncology Group Central Nervous System Effect Clinical Toxicology Central Nervous System Toxicity Grade Grade
Unable to display preview. Download preview PDF.
- 1.T. L. Phillips, T. H. Wasserman, R. J. Johnson The hypoxic cell sensitizer program in the United States, Br. J. Cancer 37:suppl. III:276 (1978).Google Scholar
- 2.T. L. Phillips, and T. H. Wasserman, Hypoxic cell sensitizer studies in the U.S., in: “Treatment of Radioresistant Cancers”, Elsevier, North Holland Press, pp. 29–40 (1979).Google Scholar
- 3.T. L. Phillips, T. H. Wasserman, R. J. Johnson, Final report on the United States Phase I clinical trial of the hypoxic cell radiosensitizer misonidazole. Submitted to Cancer (1980).Google Scholar
- 6.T. H. Wasserman, J. Stetz, and T. L. Phillips, Clinical trials of misonidazole in the United States, Cancer Clinical Trials, in press, (1980).Google Scholar
- 7.G. VanRaalte, T. L. Phillips, and T. H. Wasserman, (Abstract), Int. J. Radiat. Oncol. Biol. Phys., in press, (1980).Google Scholar